Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study
Authors' conclusion
Telitacicept appears to be a promising therapy for children with IgAV and IgAVN, effectively inducing proteinuria remission, improving systemic symptoms, and reducing the use of steroids, with favorable safety.
Study context
- Population
- Children with Immunoglobulin A vasculitis (IgAV) or immunoglobulin A vasculitis nephritis (IgAVN), single centre24 telitacicept, 30 matched controls
- Participants
- 5 / 10 / 9 / 30
- Exposure
- Telitacicept vs conventional treatment only
- IgAVn = 5
- Acute IgAVNn = 10
- Chronic IgAVNn = 9
- Controlsn = 30reference
- Outcome
- UPCR in IgAVN vs baseline
- Follow-up
- 36 weeks
Methodological detailssingle-centre, observational, matched controls
- Single-centre
- Observational
- Matched controls
Main finding
As reported in the abstract
- Urinary protein-to-creatinine ratio (UPCR) significantly decreased at 36 weeks vs baseline in both acute and chronic IgAVN
- P < 0.05
- Estimated glomerular filtration rate (eGFR) remained stable
- P > 0.05
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Steroid reduction, weeks 4–24Acute IgAVN vs Controls · significantly greater steroid reduction | P < 0.05 |
Serum IgA, IgG · 12 weeks
- Serum IgA and IgG significantly decreased after telitacicept
- P < 0.01
Original publication
Efficacy and safety of telitacicept in children with IgA vasculitis and IgA vasculitis nephritis: a single-center retrospective study. Pediatr Rheumatol Online J. Published 21 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →